‘Like a hand fitting into a glove’: Purdue-engineered compound designed to treat drug-resistant acute myeloid leukemia
20 juin 2024 10h55 HE
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., June 20, 2024 (GLOBE NEWSWIRE) -- Researchers at Purdue University’s College of Science have developed a patent-pending compound called HSN748 to treat drug-resistant acute...
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
17 juin 2024 09h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
17 juin 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Hemato-Oncology Testing Market to Cross $12.7 Billion by 2034: Industry Trends and Analysis Featuring Profiles of Leading Market Players, Including EntroGen, Cepheid, Bio-Rad Labs, ArcherDX, Qiagen
05 juin 2024 04h20 HE
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Hemato-Oncology Testing Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13 mai 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
09 mai 2024 16h05 HE
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
02 mai 2024 07h30 HE
|
Bio-Gene Technology Co Ltd
Guangzhou Bio-gene Technologies announces the Initiation of a Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1 in patients with AML
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
30 avr. 2024 08h05 HE
|
Senti Biosciences, Inc.
Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
Kura Oncology to Report First Quarter 2024 Financial Results
25 avr. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
22 avr. 2024 07h30 HE
|
Kura Oncology, Inc.
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to...